Drug intelligence / Profile preview

GBPD002

Development stage: Phase 2
Lead developer: Globe Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**GBPD002** is a biosimilar of recombinant human erythropoietin (rhEPO), developed to treat conditions requiring stimulation of erythropoiesis[2][7]. GBPD002 is a glycoprotein cytokine that acts as a hematopoietic growth factor, binding to the erythropoietin receptor (EPOR) on erythroid progenitor cells to promote their proliferation, differentiation, and survival, primarily via activation of the JAK2/STAT5 signaling cascade[7]. It has demonstrated comparable pharmacokinetic, pharmacodynamic, and safety profiles to the established erythropoietin brand Eprex, supporting its biosimilar status[2][7].

Brand names: GBPD002GBPD-002GBPD 002
Other names: recombinant erythropoietin biosimilar GBPD002

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on GBPD002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBPD002.

Explore the full profile